sparfloxacin has been researched along with amoxicillin in 23 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 11 (47.83) | 18.2507 |
2000's | 7 (30.43) | 29.6817 |
2010's | 5 (21.74) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hirayama, F; Ikeda, Y; Kawakita, T; Kuroda, T; Moriguchi, A; Sakurai, N; Sano, M; Uemori, S; Yamamoto, K | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Avdeef, A; Tam, KY | 1 |
Gozalbes, R; Pineda-Lucena, A | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Avril, JL; Donnio, PY; Gastine, C; Travert, MF | 1 |
Garau, J; Grassi, C; Hosie, J; Huchon, G; Legakis, N; Lode, H; Segev, S; Wijnands, G | 1 |
Aubier, M; Gialdroni-Grassi, G; Hosie, J; Huchon, G; Legakis, N; Lode, H; Regamey, C; Segev, S; Tolstuchow, N; Vester, R; Wijnands, WJ | 1 |
May, T; Portier, H; Proust, A | 1 |
Allegra, L; Guyen, JN; Hosie, J; Konietzko, N; Leophonte, P; Pauwels, R; Petitpretz, P | 1 |
Arvieux, C; Avril, JL; Cartier, F; Jacquelinet, C; Michelet, C; Vu, N | 1 |
Davies, BI; Dirks-Go, SI; Hoogkamp-Korstanje, JA; Kabel, P; Manson, WL; Stobberingh, EE; Vreede, RW | 1 |
Aubier, M; Geslin, P; Regamey, C; Vercken, JB; Verster, R | 1 |
Bergmann, JS; Woods, GL | 1 |
Appelbaum, PC; Hoellman, DB; Jacobs, MR; Lin, G | 1 |
Johnson, JR | 1 |
Kanayama, A; Kobayashi, I; Mochida, O; Naito, S; Saika, T; Tanaka, M; Tunoe, H | 1 |
Hashido, H; Ishigo, S; Iwata, I; Matsubara, S; Matsukawa, Y; Mikamo, H; Sawamura, H; Suematsu, H; Tamaya, T | 1 |
Katouno, Y; Kobayashi, Y; Sugita, K; Uchida, H | 1 |
5 trial(s) available for sparfloxacin and amoxicillin
Article | Year |
---|---|
Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin.
Topics: Adolescent; Adult; Aged; Amoxicillin; Clavulanic Acids; Community-Acquired Infections; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Erythromycin; Female; Fluoroquinolones; Gastrointestinal Diseases; Humans; Male; Middle Aged; Pneumonia, Bacterial; Quinolones; Treatment Failure | 1995 |
Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies.
Topics: Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Clavulanic Acids; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Erythromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Penicillins; Pneumonia, Bacterial; Quinolones; Streptococcus pneumoniae | 1996 |
Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Ofloxacin; Penicillins; Pneumonia, Bacterial; Quinolones | 1996 |
Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study.
Topics: Acute Disease; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Clavulanic Acids; Double-Blind Method; Drug Therapy, Combination; Fluoroquinolones; Haemophilus influenzae; Humans; Lung Diseases, Obstructive; Middle Aged; Moraxella catarrhalis; Quinolones; Streptococcus pneumoniae | 1996 |
Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Penicillins; Pneumonia, Pneumococcal; Quinolones; Streptococcus pneumoniae | 1998 |
18 other study(ies) available for sparfloxacin and amoxicillin
Article | Year |
---|---|
Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Drug Stability; Fluoroquinolones; Gerbillinae; Helicobacter Infections; Helicobacter pylori; Indicators and Reagents; Microbial Sensitivity Tests; Molecular Structure; Naphthyridines; Ofloxacin; Quinolones; Solutions; Structure-Activity Relationship; Ultraviolet Rays | 1998 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Bactericidal activity of ciprofloxacin and sparfloxacin. Comparison with others active antibiotics against Pasteurella multocida].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Cefpodoxime; Ceftizoxime; Ciprofloxacin; Dose-Response Relationship, Drug; Fluoroquinolones; In Vitro Techniques; Pasteurella multocida; Quinolones | 1995 |
Comparative activities of new fluoroquinolones, alone or in combination with amoxicillin, trimethoprim-sulfamethoxazole, or rifampin, against intracellular Listeria monocytogenes.
Topics: Amoxicillin; Anti-Infective Agents; Colony Count, Microbial; Dose-Response Relationship, Drug; Fluoroquinolones; HeLa Cells; Humans; Levofloxacin; Listeria monocytogenes; Ofloxacin; Quinolones; Rifampin; Sulfamethoxazole; Trimethoprim | 1997 |
Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Clarithromycin; Clavulanic Acids; Drug Evaluation; Drug Therapy, Combination; Fluoroquinolones; Haemophilus influenzae; Microbial Sensitivity Tests; Moraxella catarrhalis; Quinolones; Streptococcus pneumoniae | 1997 |
In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis.
Topics: Amoxicillin; Antitubercular Agents; Clavulanic Acid; Drug Combinations; Drug Interactions; Evaluation Studies as Topic; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Quinolones; Rifabutin | 1998 |
Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
Topics: Amoxicillin; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Streptococcus pneumoniae | 1999 |
Amoxicillin versus sparfloxacin in the treatment of presumed pneumococcal pneumonia.
Topics: Amoxicillin; Anti-Infective Agents; Fluoroquinolones; Humans; Penicillins; Pneumonia, Pneumococcal | 2000 |
Antimicrobial activity of gemifloxacin (SB-265805), a newer fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae, including fluoroquinolone-resistant isolates.
Topics: Amoxicillin; Anti-Infective Agents; Ciprofloxacin; Clavulanic Acid; Drug Resistance, Microbial; Fluoroquinolones; Gemifloxacin; Gonorrhea; Humans; Levofloxacin; Naphthyridines; Neisseria gonorrhoeae; Norfloxacin; Ofloxacin | 2000 |
[The frequency of Streptococcus pneumoniae strains and sensitivity surveillance for several antibiotics in Gifu Prefecture].
Topics: Amoxicillin; Anti-Bacterial Agents; Cefaclor; Cefdinir; Cefixime; Cefmenoxime; Cefpodoxime; Ceftizoxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Clindamycin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Imipenem; Japan; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Minocycline; Naphthyridines; Ofloxacin; Penicillin G; Penicillins; Streptococcus pneumoniae; Thienamycins | 2000 |
[Comparative in vitro activities of several antimicrobial agents against Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Gastric Mucosa; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Penicillins; Stomach Ulcer | 2002 |